Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16790838 | 0.94 | GAA (0.37) | GAAHTTCYP2D6LMNA | |
| SCHEMBL19884609 | 0.93 | GAA (0.36) | GAAHTTCYP2D6LMNA | |
| SCHEMBL19884574 | 0.93 | GAA (0.36) | GAAHTTCYP2D6LMNA | |
| SCHEMBL13554332 | 0.92 | GAA (0.36) | GAAHTTCYP2D6LMNATSHR | |
| SCHEMBL19884600 | 0.91 | GAA (0.35) | GAAHTTCYP2D6LMNA | |
| SCHEMBL13108967 | 0.88 | CYP2D6 (0.34) | GAACYP2D6LMNACYP2C19TSHR | |
| SCHEMBL4960656 | 0.88 | GAA (0.40) | GAAHTTCYP2D6LMNATSHR | |
| SCHEMBL7506478 | 0.86 | GAA (0.41) | GAAHTTCYP2D6LMNATSHR | |
| SCHEMBL15686228 | 0.86 | GAA (0.41) | GAAHTTCYP2D6LMNATSHR | |
| SCHEMBL13123818 | 0.85 | CYP2D6 (0.31) | CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1095006-B1 | DERIVATIVES OF 1-OXYL-4-HYDROXY-2,2,6,6-TETRAMETHYLPIPERIDINE AS POLYMERIZATION INHIBITORS FOR (METH) ACRYLATE MONOMERS | CIBA HOLDING INC (CH) | 2008-12-24 | — | — | EP | claimed |
| WO-2022136223-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME AND COMPOUNDS | MERCK PATENT GMBH (DE) | 2022-06-30 | — | — | WO | disclosed |
| US-11312908-B2 | Liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2022-04-26 | — | — | US | disclosed |
| US-11015123-B2 | Liquid-crystal material | MERCK PATENT GMBH (DE) | 2021-05-25 | — | — | US | disclosed |
| EP-3327103-B1 | LIQUID CRYSTAL MEDIUM, METHOD FOR THE STABILISATION THEREOF AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2020-10-14 | — | — | EP | disclosed |
| US-20200255741-A1 | LIQUID-CRYSTAL MATERIAL | MERCK PATENT GMBH (DE) | 2020-08-13 | — | — | US | disclosed |
| EP-3458549-B1 | LIQUID-CRYSTAL MATERIAL | MERCK PATENT GMBH (DE) | 2020-07-22 | — | — | EP | disclosed |
| EP-3327102-B1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2020-04-15 | — | — | EP | disclosed |
| US-20200056093-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND ELECTRONIC DEVICE | SHARP KABUSHIKI KAISHA (JP) | 2020-02-20 | — | — | US | disclosed |
| US-10465117-B2 | Liquid-crystalline medium, method for the stabilization thereof, and liquid-crystal display | MERCK PATENT GMBH (DE) | 2019-11-05 | — | — | US | disclosed |
| WO-2017198637-A1 | LIQUID-CRYSTAL MATERIAL | MERCK PATENT GMBH (DE) | 2017-11-23 | — | — | WO | disclosed |
| US-9388339-B2 | Liquid-crystalline medium, method for the stabilization thereof, and liquid-crystal display | MERCK PATENT GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| US-20150159088-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2015-06-11 | — | — | US | disclosed |
| US-8999460-B2 | Compounds and liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-8962102-B2 | — | — | 2015-02-24 | — | — | US | disclosed |
| EP-2514800-B1 | Compounds and liquid crystalline medium | MERCK PATENT GMBH (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-20140111730-A1 | Liquid-crystalline medium, method for the stabilization thereof, and liquid-crystal display | MERCK PATENT GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| EP-2722380-A2 | Liquid crystal medium, method for the stabilisation thereof and liquid crystal display | Merck Patent GmbH (DE) | 2014-04-23 | — | — | EP | disclosed |
| EP-2722381-A2 | Liquid crystal medium, method for the stabilisation thereof and liquid crystal display | Merck Patent GmbH (DE) | 2014-04-23 | — | — | EP | disclosed |
| EP-1095006-B1 | DERIVATIVES OF 1-OXYL-4-HYDROXY-2,2,6,6-TETRAMETHYLPIPERIDINE AS POLYMERIZATION INHIBITORS FOR (METH) ACRYLATE MONOMERS | CIBA HOLDING INC (CH) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150159088-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | VIM, NEFM, VCL | GAA 3565/4885HTT 3107/4885CYP2D6 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.